Your browser is no longer supported. Please, upgrade your browser.
ARNA Arena Pharmaceuticals, Inc. monthly Stock Chart
ARNA [NASD]
Arena Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.09 Insider Own0.59% Shs Outstand302.95M Perf Week6.98%
Market Cap418.07M Forward P/E- EPS next Y-0.35 Insider Trans2.88% Shs Float246.53M Perf Month-5.48%
Income-22.50M PEG- EPS next Q-0.07 Inst Own46.40% Short Float3.61% Perf Quarter-4.17%
Sales124.00M P/S3.37 EPS this Y79.40% Inst Trans0.06% Short Ratio4.10 Perf Half Y-14.29%
Book/sh0.16 P/B8.62 EPS next Y-12.90% ROA-10.70% Target Price3.25 Perf Year-22.91%
Cash/sh0.30 P/C4.61 EPS next 5Y- ROE-95.50% 52W Range1.20 - 2.16 Perf YTD-2.82%
Dividend- P/FCF- EPS past 5Y35.00% ROI-16.30% 52W High-37.04% Beta-0.99
Dividend %- Quick Ratio1.80 Sales past 5Y57.70% Gross Margin87.60% 52W Low13.33% ATR0.06
Employees106 Current Ratio1.90 Sales Q/Q994.90% Oper. Margin-13.90% RSI (14)43.47 Volatility3.59% 3.43%
OptionableYes Debt/Eq1.63 EPS Q/Q226.30% Profit Margin-18.20% Rel Volume0.72 Prev Close1.38
ShortableYes LT Debt/Eq1.55 EarningsMar 14 AMC Payout- Avg Volume2.17M Price1.36
Recom2.70 SMA20-2.47% SMA50-6.33% SMA200-12.00% Volume1,475,086 Change-1.45%
Sep-15-16Initiated FBR & Co. Outperform $6
Mar-01-16Reiterated RBC Capital Mkts Sector Perform $2 → $1.50
Nov-11-15Reiterated RBC Capital Mkts Sector Perform $5 → $2
Oct-28-15Reiterated WallachBeth Buy $6 → $4
May-12-15Reiterated WallachBeth Buy $8 → $6
Jan-23-15Initiated RBC Capital Mkts Sector Perform $5
Aug-07-14Reiterated WallachBeth Buy $9 → $8
Nov-15-13Initiated WallachBeth Buy $9
Oct-03-13Initiated Cowen Market Perform $4.50
Oct-25-10Reiterated Barclays Capital Underweight $3 → $2
Sep-20-10Reiterated UBS Neutral $7 → $2
Sep-17-10Downgrade Davenport Buy → Neutral
Sep-14-10Downgrade Barclays Capital Equal Weight → Underweight $4 → $3
Aug-23-10Reiterated UBS Neutral $3.50 → $7
Jul-16-10Downgrade Rodman & Renshaw Mkt Perform → Mkt Underperform $1
Jul-02-10Reiterated UBS Buy $40 → $38
Feb-04-10Upgrade Rodman & Renshaw Mkt Underperform → Mkt Perform
Dec-17-09Initiated Jefferies & Co Hold $4
Sep-21-09Downgrade Leerink Swann Outperform → Mkt Perform $6
Sep-18-09Downgrade Rodman & Renshaw Mkt Perform → Mkt Underperform $3
Apr-21-17 04:01PM  Arena Pharmaceuticals Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares PR Newswire
Apr-19-17 02:51PM  Arena Pharmaceuticals, Inc. Value Analysis (NASDAQ:ARNA) : April 19, 2017 Capital Cube
09:37AM  Arena Pharma (ARNA) Down After Underwritten Public Offering Zacks
07:30AM  Biotech Industry Outperforming Major Indexes in 2017: Today's Research Reports on Arena Pharmaceuticals and Cytokinetics Accesswire
02:57AM  Why Is Arena Pharmaceuticals (ARNA) Down 11.3% Since the Last Earnings Report? Zacks
Apr-18-17 12:52PM  Arena Takes a Beating After Lackluster Secondary, Cytokinetics Pops: Biotech Movers TheStreet.com -13.51%
11:05AM  Why Arena Pharmaceuticals Stock Is Getting Hammered Today Motley Fool
10:35AM  Arena Pharmaceuticals Sinks After Announcing Secondary Offering 24/7 Wall St.
08:31AM  Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARNA-US : April 18, 2017 Capital Cube
Apr-17-17 10:15PM  Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock PR Newswire
08:30AM  Arena Pharmaceuticals Announces Multiple Presentations at ASPET 2017 at Experimental Biology PR Newswire
Apr-11-17 06:00AM  The State of Play in Axovant Sciences Investopedia
Apr-10-17 03:48PM  Why Arena Pharmaceuticals Stock Slimmed Down in March Motley Fool
Apr-07-17 03:50PM  ETFs with exposure to Arena Pharmaceuticals, Inc. : April 7, 2017 Capital Cube
Apr-06-17 09:11AM  New Strong Sell Stocks for April 6th Zacks
Mar-28-17 09:30AM  Today's Research Reports on Biotech Stocks to Watch: Arena Pharmaceuticals and Immunomedics Accesswire
08:07AM  Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARNA-US : March 28, 2017 Capital Cube
Mar-27-17 03:49PM  ETFs with exposure to Arena Pharmaceuticals, Inc. : March 27, 2017 Capital Cube
08:30AM  Arena Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference on April 4th PR Newswire
Mar-20-17 09:01AM  Arena Pharmaceuticals, Inc. :ARNA-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Capital Cube
08:30AM  Arena Pharmaceuticals Appoints Dr. Preston Klassen, M.D., M.H.S. as Executive Vice President, Research and Development and Chief Medical Officer PR Newswire
Mar-18-17 01:04PM  ARENA PHARMACEUTICALS INC Financials
Mar-17-17 10:05AM  Arena Pharmaceuticals, Inc. :ARNA-US: Earnings Analysis: 2016 By the Numbers : March 17, 2017
Mar-15-17 02:36PM  How to Trade Wednesday's Most Active Stocks: Lloyds, Arena Pharma, MSCI and More TheStreet.com +12.68%
01:28PM  Why Arena Pharmaceuticals Stock Is Surging Higher Today Motley Fool
12:10PM  Wednesdays Biggest Biopharma Movers 24/7 Wall St.
11:54AM  Arena Pharmaceuticals (ARNA) Posts Q4 Earnings, Revenues Up
11:16AM  7 Most Popular Diet Pills That Work Fast Without Exercise at Insider Monkey
09:32AM  Biotech Premarket Movers: Arena, Immunomedics, Aralez
08:12AM  ARENA PHARMACEUTICALS INC Files SEC form 10-K, Annual Report
Mar-14-17 10:06PM  Edited Transcript of ARNA earnings conference call or presentation 14-Mar-17 8:30pm GMT
04:22PM  Arena Pharmaceuticals beats 4Q profit forecasts
04:10PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:01PM  Arena Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2016 Financial Results PR Newswire
07:07AM  Q4 2016 Arena Pharmaceuticals Inc Earnings Release - After Market Close
Mar-13-17 09:00AM  Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARNA-US : March 13, 2017
Mar-09-17 10:48AM  10 Best Performing Weight Loss Companies And Their Programs at Insider Monkey
Mar-08-17 04:30PM  Arena Pharmaceuticals to Present at the 27th Annual Oppenheimer Healthcare Conference PR Newswire
09:30AM  Biotech's Fall as President Trump to Address Pricing Concerns: Today's Research Reports on Arena Pharmaceuticals and Merrimack Pharmaceuticals Accesswire
Mar-06-17 04:30PM  Arena Pharmaceuticals to Provide Corporate Update and Release Fourth Quarter and Full-Year 2016 Financial Results on Tuesday, March 14, 2017 GlobeNewswire
Feb-27-17 08:21AM  Arena Pharmaceuticals (ARNA) Q4 Earnings: What to Expect? +6.80%
Feb-22-17 08:14AM  Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ARNA-US : February 22, 2017
Feb-14-17 09:02AM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
08:30AM  Arena Pharmaceuticals Appoints Three New Members to Board of Directors PR Newswire
Feb-09-17 08:30AM  Arena Pharmaceuticals Announces Three Upcoming Presentations at the 12th Congress of European Crohn's and Colitis Organisation - Inflammatory Bowel Diseases 2017 PR Newswire
Jan-30-17 07:22AM  Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARNA-US : January 30, 2017
Jan-13-17 08:25AM  Why Arena Pharmaceuticals Stock Sank in 2016 at Motley Fool
Jan-11-17 03:24PM  VIVUS Licenses Rights to PAH Drugs from Selten Pharma
Jan-09-17 06:07PM  Puma (PBYI) Expands Study Cohort for Lead Candidate PB272
08:10AM  Vertex Pharma Issues Disappointing 2017 Orkambi Outlook
Jan-06-17 04:48PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure
10:40AM  Arena Pharmaceuticals Dumps Belviq Weight Loss Drug at Investopedia
08:43AM  Genocea Stock Up on Positive Genital Herpes Infections Data
08:32AM  Biogen Licenses Amunix's XTEN Technology for Factor IX Drug
Jan-05-17 10:37AM  Arena, Eisai Modify Marketing & Supply Agreement for Belviq
09:38AM  Evoke Diabetic Gastroparesis Drug Gimoti Positive in Phase III
08:16AM  Allergan (AGN) Liletta sNDA Accepted for Review in the U.S.
08:07AM  Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARNA-US : January 5, 2017
Jan-04-17 09:01PM  Eisai Acquires All Global Development and Marketing Rights for Chronic Weight Management Treatment Lorcaserin ACN Newswire
04:23PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Ex
04:05PM  Arena Pharmaceuticals and Eisai Amend Marketing and Supply Agreement for BELVIQ Globally PR Newswire
09:43AM  Clovis Declares Pricing of Upsized Offering of Common Stock
08:33AM  Allergan Natrelle Inspira Breast Implants Approved in the U.S.
Jan-03-17 08:53AM  Is Vertex Pharma (VRTX) Poised for a Turnaround in 2017?
Dec-27-16 10:17AM  Arena Pharmaceuticals, Inc. Value Analysis (NASDAQ:ARNA) : December 27, 2016
Dec-26-16 07:29AM  Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARNA-US : December 26, 2016
Dec-19-16 01:30PM  Eisai and Arena Pharmaceuticals Announce Regulatory Approval of BELVIQ® (lorcaserin HCl) in Brazil PR Newswire
12:58PM  ETFs with exposure to Arena Pharmaceuticals, Inc. : December 19, 2016
Dec-18-16 02:27PM  Is Arena Pharmaceuticals, Inc. (ARNA) A Good Stock To Buy? at Insider Monkey
07:35AM  Tax-Loss Selling: 3 Stocks to Dump Right Now at Motley Fool
Dec-13-16 08:30AM  Arena Pharmaceuticals to Present at the 35th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-08-16 12:12PM  ETFs with exposure to Arena Pharmaceuticals, Inc. : December 8, 2016
Dec-07-16 08:30AM  Arena Pharmaceuticals Completes Enrollment in Ralinepag Phase 2 Clinical Trial for Pulmonary Arterial Hypertension (PAH) PR Newswire -5.41%
Dec-02-16 02:47PM  The Worst Marijuana Stocks in 2016 at Motley Fool
Nov-30-16 08:30AM  Arena Pharmaceuticals Announces Four Upcoming Presentations at the 2016 Advances in Inflammatory Bowel Diseases: Crohn's & Colitis Foundation's Clinical and Research Conference PR Newswire
Nov-28-16 06:52PM  Should You Follow Hedge Funds Into Healthways, Inc. (HWAY)? at Insider Monkey -5.30%
11:52AM  ETFs with exposure to Arena Pharmaceuticals, Inc. : November 28, 2016
Nov-22-16 11:08AM  Arena Pharmaceuticals, Inc. :ARNA-US: Earnings Analysis: Q3, 2016 By the Numbers : November 22, 2016
Nov-15-16 01:12PM  ETFs with exposure to Arena Pharmaceuticals, Inc. : November 15, 2016
Nov-14-16 07:56AM  Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARNA-US : November 14, 2016
Nov-09-16 04:30PM  Arena Pharmaceuticals to Present at the 28th Annual Piper Jaffray Healthcare Conference PR Newswire
04:09PM  ARENA PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
08:30AM  Arena Pharmaceuticals Announces Poster at the American Heart Association (AHA) Scientific Sessions 2016 PR Newswire
Nov-08-16 11:06AM  3 Things You Really Need to Know About Arena Pharmaceuticals, Inc. Q3 Results at Motley Fool
08:11AM  Arena (ARNA) Q3 Loss Lower than Expected, Revenues Rise
07:29AM  Arena Pharmaceuticals Shed Even More Weight in October at Motley Fool
Nov-07-16 06:37PM  Edited Transcript of ARNA earnings conference call or presentation 7-Nov-16 9:30pm GMT +5.76%
05:40PM  Arena Pharmaceuticals reports 3Q loss
04:37PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:05PM  Arena Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update PR Newswire
07:07AM  Q3 2016 Arena Pharmaceuticals Inc Earnings Release - After Market Close
Nov-04-16 05:39PM  Arena (ARNA) Q3 Earnings: Will the Stock Pull a Surprise?
Nov-03-16 08:05AM  Eisai and Arena Pharmaceuticals Announce Presentation of BELVIQ® (lorcaserin HCl) Data at 2016 Annual Obesity Week Meeting PR Newswire
Oct-31-16 04:30PM  Arena Pharmaceuticals to Release Third Quarter 2016 Financial Results and Provide Corporate Update on Monday, November 7, 2016 PR Newswire
Oct-28-16 01:33PM  Telling a Half-Truth Doesn't Work for Drugmaker at Bloomberg
Oct-18-16 09:23AM  Biotech Review DVAX Vaccine Faces Crucial PDUFA Date, CLDX Seeks Fast-Track Orphan Drug Status CNW Group
Oct-17-16 09:50AM  ETFs with exposure to Arena Pharmaceuticals, Inc. : October 17, 2016
08:44AM  Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ARNA-US : October 17, 2016
Oct-11-16 11:14AM  Why Arena Pharmaceuticals Is Finally Showing Some Signs of Life at Motley Fool
08:30AM  Arena Pharmaceuticals Announces Acceptance of Late Breaking Etrasimod Abstract at the United European Gastroenterology Week (UEGW) Meeting PR Newswire
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for various therapeutic areas in the United States and Switzerland. The company's proprietary investigational clinical programs include etrasimod (APD334), which is in Phase IIb evaluation for ulcerative colitis, as well as is in Phase IIa evaluation for dermatologic extraintestinal manifestations in inflammatory bowel disease, pyoderma gangrenosum, and primary biliary cholangitis; ralinepag that is in Phase IIb evaluation to treat pulmonary arterial hypertension; and APD371, which is in Phase IIa evaluation for the treatment of pain associated with Crohn's disease. It has collaboration agreements with Eisai Inc.; Eisai Co., Ltd.; Axovant Sciences Ltd.; and Boehringer Ingelheim International GmbH. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Munshi AmitPresident and CEOApr 26Buy1.4150,00070,50051,875Apr 27 08:06 AM
White Christine AnnaDirectorJun 13Sale1.9918,72837,29985,529Jun 15 08:55 PM